Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition. In cancer patients,

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically meaningful, and Pfizer is now thinking about starting a phase 3 programme for the drug next year.

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition

Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.

Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.

Pfizer’s experimental cancer weight loss drug helped patients regain weight in a mid-stage study giving fresh promise for the dangerous muscle-wasting condition